The DOI matches its Crossref record.
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
Abstract
OBJECTIVE: To determine the incidence of significant liver enzyme elevations following the initiation of protease inhibitor (PI)-based antiretroviral therapy (ART) with or without pharmacokinetic boosting with ritonavir (RTV), and to define the role of chronic viral hepatitis in its development. DESIGN: Prospective, cohort analysis of 1161 PI-naive, HIV-infected patients receiving RTV-boosted (lopinavir, indinavir and saquinavir) and unboosted PI-based ART (indinavir, nelfinavir) that had at least one liver enzyme measurement before and during therapy. METHODS: The incidence of grade 3 and 4 liver enzyme elevations among persons with and without hepatitis B and/or C co-infection treated with PI-based ART were compared. Severe hepatotoxicity was defined as an increase in serum liver enzyme >/= 5-times the upper limit of the normal range or 3.5-times an elevated baseline level. RESULTS: The incidence of grade 3 or 4 elevations among PI-naive patients was: nelfinavir, 11%; lopinavir/RTV (200 mg/day), 9%; indinavir, 13%; indinavir/RTV (200-400 mg/day), 12.8%; and saquinavir/RTV (800 mg/day), 17.2%. The risk was significantly greater among persons with chronic viral hepatitis (63% of cases); however, the majority of hepatitis C virus (HCV)-infected patients treated with nelfinavir (84%), saquinavir/RTV (74%), indinavir, 86%, indinavir/RTV (90%) or lopinavir/RTV (87%) did not develop hepatotoxicity. CONCLUSIONS: Our data suggest that the lopinavir/RTV is not associated with a significantly increased risk of hepatotoxity among HCV-infected and uninfected patients compared with an alternative PI-based regimen, nelfinavir. Accordingly, other medication-related factors (e.g, efficacy and non-hepatic toxicity) should guide individual treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Soriano, V., Puoti, M., Sulkowski, M., Cargnel, A., Benhamou, Y., Peters, M., Mauss, S., Bräu, N., Hatzakis, A., Pol, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3281084e4d · Cited by 349
Self-citationHepatotoxicity of antiretrovirals: Incidence, mechanisms and management
Núñez, M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.027 · Cited by 313
Clinical Biochemistry of Hepatotoxicity
P Sharma, O. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s4-001 · Cited by 305
Banerjee, A., Abdelmegeed, M. A., Jang, S., & Song, B.-J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076850 · Cited by 35
Metadata
- Authors
- Sulkowski, M. S., Mehta, S. H., Chaisson, R. E., Thomas, D. L., & Moore, R. D.
- Venue
- AIDS
- Published
- 2004-11
- Volume
- 18
- Issue
- 17
- Pages
- 2277-2284
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2056885245
- Cited by
- 162
- References
- 0
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. https://app.cochat.ai/papers/10.1097/00002030-200411190-00008
- The paper
- Sulkowski, M. S., Mehta, S. H., Chaisson, R. E., Thomas, D. L., & Moore, R. D. (2004). Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. https://doi.org/10.1097/00002030-200411190-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.